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The Role of the Primary Care 




Dementia is a frequent complication of Parkinson’s disease with an annual 
incidence of around 10% of patients with Parkinson’s disease. If dementia occurs 
in patients with Parkinson’s disease, it is typically many years or decades after 
the onset of Parkinson’s disease. It is devastating for both patient and family or 
caretaker when a patient with Parkinson’s disease develops dementia. Primary care 
physician is at the center of the care team for the patient. This chapter discusses 
the pivotal role of the primary care physicians in the management of patients with 
Parkinson’s disease dementia. A guide is provided to emphasize the art of practice 
for Primary care physicians which consists of knowing when and how to introduce 
a comprehensive ongoing care plan for individual patient with Parkinson’s disease 
dementia. Recommendations for maintaining some patients with Parkinson’s 
disease dementia in a status of relative independence are discussed. Indications for 
initiation of palliative care are also discussed.
Keywords: Primary care physicians, Parkinson’s disease dementia, management, 
palliative care
1. Introduction
Parkinson’s disease dementia (PDD) is a well-known complication of Parkinson’s 
disease (PD), with an annual incidence of around 10% of patients with PD and a 
cumulative prevalence of 75–90% of those with a disease duration of 10 years or 
more [1–3]. Dementia is an overall term that describes a wide range of symptoms 
associated with a decline in memory or other thinking skills severe enough to reduce 
a person’s ability to perform independent activities of daily living (IADLs) [4]. 
Symptoms of dementia can be seen in most of the neurodegenerative diseases, such 
as Alzheimer’s disease (AD), vascular dementia (VD), dementia with Lewy bodies 
(DLB), Creutzfeldt-Jakob disease (CJD), frontotemporal dementia, Huntington’s 
disease, normal pressure hydrocephalus [5, 6]. The general risk factors for dementia 
include lower education, hypertension, hearing impairment, smoking, obesity, 
depression, physical inactivity, diabetes, low social contact, excessive alcohol 
consumption, traumatic brain injury, and air pollution [7]. It is devastating for both 
patient and family or caretaker when a patient with PD develops dementia because 
both PD and dementia have a protracted course, with progressive but insidious 
development of disability [8]. Primary care physicians (PCPs) stand in a unique 
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position for caring for patients from early to terminal stage of their life and play an 
important role in the management of PDD patients, including in screening, diag-
nosis, and treatment. It is important to provide individual, realistic, and affordable 
options of care to every unique patient and his/her family [9, 10].
2. Screening for the early symptoms and signs of PDD
PD impacts people in different ways. Not everyone will experience all the 
symptoms of PD at the same time or follow the same pattern. But PCPs should be 
familiar with the common symptoms or typical patterns of progression in PD that 
are defined in stages [11–13]. PCPs should also know the risk factors that make 
PD patients more likely to experience dementia because the clinical symptoms of 
both syndromes can overlap to a high degree. PCPs should always consider seek-
ing reversible medical conditions that can affect mental function in PD patients. 
A flowsheet (Table 1) for screening generated here should help PCPs and their 
team to achieve this goal during a patient’s routine annual wellness visit (AWV) or 
general visit.
In addition to above mentioned risk factors [7], genetic risk factors are concern-
ing too. One gene, identified to be a risk factor, is the apolipoprotein E gene which 
presents in three allelic forms (ε2, ε3, and ε4), of which the ε4 allele is a risk factor 
for AD [23, 24]. Recognizing some other factors in PD patients is also important for 
early diagnosis of PDD [25, 26]. Those other factors include advanced age at time of 
diagnosis of PD, experiencing excessive daytime sleepiness, hallucinations before 
the onset of other dementia symptoms, a history of mild cognitive impairment, 
more severe motor impairment symptoms than most people with PD, having a 
specific PD symptom that causes a person to have difficulty starting to take a step or 
to halt mid-step while walking.
Items Purpose
Age recognize this is a risk factor
Stage of PD severity of motor impairment from PD, another risk factor for PDD




screening possible high-risk patients. If it is negative, follow up periodically. If 
it is positive, further investigation is needed.
Geriatric Depression 
Scale [15, 16]
search for mood disorders
PHQ-9 screen for 
depression [17, 18]
further evaluation of depression
MoCA [19] early detection of cognitive impairment
Qmci [20] differentiating MCI and NC
MMSE + CDT [21, 22] to stage mental dysfunction, better specificity and sensitivity
AWV: annual wellness visit; PHQ-9: patient health questionnaire-9; MCI: mild cognitive impairment; NC: normal 
cognitive. MoCA: Montreal cognitive assessment; Qmci: quick mild cognitive impairment; MMSE: mini-mental state 
examination. CDT: clock drawing test.
The information needed to arrive at the diagnosis requires the clear demonstration that cognitive impairment 
negatively impacts daily living. This issue is determined by the patient and caregiver interview, and generally focuses 
on the patient’s autonomy, the ability to manage finances, to cope in social situations, and to utilize equipment that is 
part of daily living.
Table 1. 
For routine AWV in PD patient in addition to routine questionnaire.
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It is important to search for reversible medical conditions affecting mental dys-
function that may mimic dementia. Electrolyte imbalance, such as hyponatremia 
or hypernatremia, may cause neuropsychiatric manifestations [27–29]. A personal-
ity change such as increasing irritability may be a symptom of hypernatremia, 
hypercalcemia, hypocalcemia, hypophosphatemia, or hypomagnesemia. In most 
instances, correction of such underlying electrolyte imbalance will alleviate the 
psychiatric symptoms. PCPs should pay close attention to age-related limitations 
of fluid homeostasis, especially in PD patients because that can change the mental 
function in PD patients gradually and insidiously. Vitamin D deficiency has been 
associated with neuropsychiatric conditions such as PD, schizophreniform disor-
der, multiple sclerosis (MS), AD and autism spectrum disorder [30]. PCPs should 
always be alerted that the side effects of medications can also cause various symp-
toms and signs of mental disorders that can mimic dementia [31]. Those common 
drugs include anxiolytics (Benzodiazepines), antiseizure medications (e.g. carba-
mazepine), antidepressants (e.g. tricyclics), narcotics (e.g. hydrocodone), certain 
medications for PD (e.g. pramipexole, ropinirole), some hypertension medications 
(e.g. beta-blockers), sleeping medications (non-benzodiazepine, zolpidem.), medi-
cations for incontinence (anticholinergics, oxybutynin.), and some antihistamines 
(first generation, e.g. hydroxyzine and diphenhydramine).
It is unclear whether early detected cognitive impairment and interventions for 
dementia patients have a significant effect on their long-term outcomes [32, 33]. But 
early detection of cognitive impairment can allow for identification and treatment 
of reversible causes. It also may help patients understand and adhere to medical 
treatment plans and provide a basis for advance planning for patients and their 
families [34]. Unfortunately, underdiagnosis of Alzheimer’s and other dementias in 
the primary care setting is not uncommon [35].
Many screening tools have been developed for medical providers to identify 
dementia patients earlier. These can be used for screening in PD patients. These 
tools are summarized in Table 2. A dementia screening indicator is generated to 
help PCPs plan the next steps of management [14]. First, it starts with three simple 
questions if you think your patient may have cognitive impairment based on (1) 
your observations, (2) concerns of the patient or (3) concerns of family or others. If 
the answer is yes for one of these three questions, the patient should be screened for 
cognitive impairment. Second, is the patient 80 or older? If yes, the patient should 
be screened for cognitive impairment. If not 80 or older, the dementia screening 
indicator should be administered. The dementia screening indicator consists of 7 
items that include (1) age, (2) years of education, (3) body mass index (BMI), (4) 
history of type 2 diabetes, (5) history of stroke, (6) function of management of 
Screening tool Characteristic Usage
Screen Indicator [35] simple, easily administered in 
PCP settings.
identify high risk patients for MCI and 
dementia
MoCA [14] early detection of cognitive 
impairment
High specificity and sensitivity for screening 
MCI
Qmci [19] needs more administrate effort more sensitive in differentiating MCI and 
NC
MMSE [20] comprehensive evaluation Able to stage dementia, but less sensitive to 
screen MCI
MCI: mild cognitive impairment; NC: normal cognitive. MoCA: Montreal cognitive assessment; Qmci: quick mild 
cognitive impairment; MMSE: mini-mental state examination.
Table 2. 
Comparison of different screening tools for mental status.
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money or medication and (7) depression. If the total point score is more than 22, 
the patient should be screened for cognitive impairment, with an instrument such 
as those described below [14].
One commonly used screening tool is the Montreal Cognitive Assessment 
(MoCA; range 0–30; follow-up evaluation to screening recommended if score is 
<26). MoCA requires about 10–15 minutes to administer and is useful in early detec-
tion of cognitive impairment, including MCI with executive dysfunction [19].
The quick mild cognitive impairment (Qmci) has six domains with total score 
100; five orientation items (country, year, month, day, and date with a maximum 
score of 10), five registration items (score ≤ 5) and a clock drawing test (score ≤ 15), 
each scored within 1 min. It also has a delay recall (DR) section (timed at 20 seconds 
with score ≤ 20), a verbal fluency (VF) test (in 60 seconds with score ≤ 20) and a 
logical memory (LM) test with 30 seconds for administration and 30 seconds for 
response (score ≤ 30). It can be administered and scored in ~5 minutes. The Qmci 
is more sensitive than the Standard Mini-Mental State Examination (SMMSE) in 
differentiating MCI and normal cognition (NC), making it a useful test, for MCI in 
clinical practice, especially for older adults [20].
The Mini-Mental State Examination (MMSE) that was developed more than 4 
decades ago is still a gold standard exam for comparison. It is a brief test, taking 
~7 to 10 minutes to complete. The pooled estimate across 15 studies resulted in 
89 percent sensitivity (95% CI, 0.85 to 0.92) and 89 percent specificity (95% CI, 
0.85 to 0.93) to detect dementia at a cutoff of ≤23 or ≤ 24 [21]. It is less sensitive 
to the presence of MCI and less thoroughly evaluated in the domains of executive 
function, higher-level language skills, and complex visuospatial processing. The 
most sensitive combination of screening tools is the MMSE and Pfeffer Functional 
Activities Questionnaire (PFAQ ) (94.1%). The best specificity is the combination of 
the MMSE and Clock Drawing test (CDT) [22, 36].
3. Diagnosis of PDD
After the clinical bedside screening test with suspicious PDD as shown in 
Table 1, orchestrating further investigations as outlined in Table 3 should be 
the next step to obtain more evidence to make the diagnosis of PDD. Laboratory 
studies and imagining studies should be carried out before making the diagnosis. 
Obtaining basic laboratory data on complete blood count (CBC), comprehensive 
Items needed to be done Purpose
Review list of medications that patient is taking search for side effects of medications.
Laboratory investigation: CMP, CBC, lipid, TSH, B12, 
CRP
search for reversible causes of mental function 
change.
Imaging study (MRI of head) rule out other pathology, identify atrophy of 
the brain.
Referral for neurological consultation confirm diagnosis
nonpharmacological intervention improve symptoms
Pharmacological treatment prevent or delay the progression of dementia
Health maintenance care preserve the ability for daily activities
Palliative care/hospice improve quality of life
Table 3. 
Steps for management of suspected PDD patient.
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metabolic panel (CMP), thyroid stimulating hormone (TSH) should be done to 
understand the basic homeostatic condition of the patients. Checking the levels of 
vitamin B12, B1, and B6 is proper to search for a reversible pathological cause of 
mental function change. Brain imaging studies, MRI or CT, will help to distinguish 
common pathological conditions, including hydrocephalus, atrophy of the brain, 
vascular disease, or tumor [37, 38].
Criteria to establish the diagnosis of PDD are depicted in Figure 1. There are 
feature domains in these criteria, including features of PD and dementia as well as 
uncertain features. In the end, a collaborative neurological consultation should be 
considered to make the diagnosis of PDD [39–43].
4. Treatment guidelines for PDD
The fundamental goals of treatment for PPD patients are to reduce suffering 
caused by the cognitive and accompanying symptoms, while delaying progressive 
cognitive and physical decline. How to reach these goals is a challenge to medi-
cal providers, patients, and families because the severity of PD, mood disorders, 
hearing defects, and mental function declining can overlap and affect each other. 
That needs comprehensive evaluation, planning, and cooperation/coordination 
with neurologists. An algorithm shown in Figure 2 will help PCPs to orchestrate the 
treatment plan with patients and their families.
4.1 Non-pharmacological intervention for PDD
The non-pharmacological interventions that combine diet, exercise, cogni-
tive training, and vascular risk monitoring improve cognition in people at risk for 
cognitive decline [44–46]. Physical exercise, both aerobic (walking, swimming) 
and anaerobic/conditioning (resistance training, Tai chi), improves cardiovascular 
health through benefits on blood pressure and stroke risk [47]. Some trials suggest 
these interventions may positively affect cognitive and physical function and pro-
mote patients’ functional independence, improve their well-being and that of their 
Figure 1. 
Criteria for diagnosis of PDD patient.
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caregivers. Cognitive training and activities such as reading and playing cognitively 
engaging games (e.g., chess, bridge) may help maintain cognition and function, 
improve processing speed, and reduce daytime sleepiness [48].
Music therapy may help maintain cognition or improve quality of life, as some 
studies revealed that recovery of verbal memory and focused attention improved 
significantly in patients who listened to their favorite music daily. Besides the 
improvement in cognitive functions, there was also a substantial mood improve-
ment in this group of patients [49]. Falls have several psychosocial impacts, includ-
ing fear of falling and reduced self-efficacy, leading to decreased independence, 
reduced social participation and diminished health-related quality of life [50]. 
Prescribing cane, walker, or physical and occupational therapies for prevention 
of falling is one of the responsibilities of PCPs. Moderate intensity outdoor group 
activities like Nordic Walking and Walking seem to improve motor and non-motor 
symptoms in patients with Parkinson’s disease [51]. Physical activity may assuage 
the degeneration of motor skills, lessen depression, and increase the quality of life 
of PDD patients.
4.2 Pharmacologic management for PDD
As described above, PCPs should oversee all medications that PDD patients 
take before considering pharmacologic treatment for dementia symptoms in 
PDD patients, because PDD patients usually take medications for PD and other 
comorbidities. PCP should be familiar with the most common pharmacologic 
therapies for PD patients, although these are usually initiated by neurologists. 
These medications include carbidopa-levodopa, monoamine oxidase-B inhibitors, 
and dopamine agonists. Knowing the effects and side effects of these medica-
tions will help PCP to recognize when mental status changes in PD patients are 
attributable to medication side effects or interactions of medications. It will also 
help PCPs avoid the interaction of medications when prescribing therapeutic 
medications either for symptoms of dementia or for other medical conditions. 
Before any medication is prescribed, potential side effects should be counseled, 
fully disclosed, and well explained (to the best of your knowledge) to patients and 
Figure 2. 
Algorithm workflow for management of PDD patient.
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their families or caregivers. This would be critical for those with limited mental 
capacity to increase compliance and to decrease avoidable incidents. In addition, 
based on our clinical experience, for lower body mass patients, low-dose initiation 
of medication and slow titration should be considered. Effective treatment moni-
toring requires periodic reevaluation of cognition, function, neuropsychiatric and 
behavioral symptoms, and medication reconciliation. Five drugs, 4 of which are 
currently available for prescription in the United States, yield modest symptom-
atic benefit for cognitive symptoms of AD dementia [38]. These drugs may be also 
beneficial for PDD patients. Their usages are discussed below and summarized in 
Table 4.
4.2.1 Acetylcholinesterase inhibitors
This class of medications can exhibit significant clinical impact in mild to 
moderate dementia patients and can also benefit severe dementia patients. 
Acetylcholinesterase inhibitors, including Donepezil, Rivastigmine and 
Galantamine, inhibit the brain enzyme acetylcholinesterase, thereby promoting 
relative increases in acetylcholine abundance at the synaptic cleft for cholinergic 
neurotransmission. Donepezil 5 to 10 mg can be taken once a day orally. This is the 
one most widely used. Side effects of nausea, gastrointestinal (GI) cramps, and 
dizziness could be minimized by being taken after dinner. Rivastigmine 1.5 to 6 mg 
twice daily orally, or 4.6 to 9.5 mg transdermal patch once a day is another option. 
Clinical trials in DLB and PDD have established this agent’s clinical efficacy better 
than other drugs in this class. Another cholinergic drug is Galantamine 4 to 12 mg 
twice a day orally or extended release 8 to 24 mg once a day orally. This agent has 
shown less consistent benefit on function and behavior. Tacrine is no longer being 
used clinically because of liver toxicity, and the above newer agents have better 
tolerance profiles.
4.2.2 Memantine (Namenda)
Memantine is one of the N-methyl-D-aspartate (NMDA) non-competitive 
antagonists which might slow down the neurodegenerative process by block-
ing Glutamate’s overstimulation of the NMDA receptors, and thus reduce 
excitotoxicity. Memantine alone or combined with Donepezil is another option 
commonly used for moderate to severe Alzheimer’s disease. A meta-analysis 
reported that use of memantine to treat behavioral and psychological symptoms 
of dementia (BPSD) yielded modest decreases in scores on the Neuropsychiatric 
Inventory Questionnaire and improvement of symptoms, although sedation 
was reported to be a major side effect [38]. Memantine can be taken 5 to 10 mg 
twice a day orally or extended-release form 7 to 28 mg once a day orally. This 
agent should be considered to initiate at the moderate to severe stages of PDD, 
because severe dementia in PD most commonly has concomitant AD pathology. 
In addition to the above 2 categories of drugs, the following other medications 
that are commonly used in PDD patients are also addressed in below and in 
Table 4.
4.2.3 Anti-Parkinsonian agents
Selegiline 5 mg twice a day orally is also commonly used. Despite lack of confir-
matory outcome data, some believe that this anti-Parkinsonian disease medication 
may have a neuroprotective effect against PDD, based largely on animal models.
Dementia in Parkinson’s Disease
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Medications commonly used in PCP setting for the pharmacologic management of PDD
A. Cholinesterase inhibitors.
1 Donepezil (Aricept) first line to choose, it should be taken after dinner to 
lessen the impact of GI side effects.
2 Rivastigmine (Exelon) Topical patch, Rivastigmine will decrease GI side effects 
and oral medication burden
B. NMDA antagonist.
1 Memantine (Namenda) for moderate to severe dementia, combined with 
Cholinesterase inhibitor showing better efficacy and 
less GI side effects
C. Neuroleptics agents
1 Quetiapine (Seroquel) commonly first to choose for relative safety profile for 
sedation and wider dosing range to titrate
2 Olanzapine (Zyprexa) effective against psychiatric symptoms but less 
favorable metabolic impacts




1 Escitalopram (Lexapro) low dose initiation, better option towards anxious 
clinical manifestation
2 Citalopram (Celexa) good alternative for Escitalopram
3 Sertraline (Zoloft) long clinical usage and experience for positive 
psychiatric symptoms
4 Fluoxetine (Prozac) long clinical usage and experience for negative 
psychiatric symptoms
b. the Others
1 Mirtazapine (Remeron) well adopted in geriatric population for hypnotic and 
appetite enhancement profiles
2 Trazodone classical and safe sleep aid in low dose
3 Bupropion (Wellbutrin) less sexual function disturbance and stamina boosting 
characters considered
4 Venlafaxine (Effexor) good feature for general anxiety symptoms
5 Nortriptyline (Pamelor) well adopted for muscle relaxing, hypnotic and appetite 
boost but alert on anticholinergic side effect in geriatric 
population
E. Anxiolytics, anticonvulsant, and hypnotic medications
1 Buspirone less clinical effectiveness but very safety profile favored 
on anxiety background management
2 Valproic acid (Depakote) mood stabilizer or clinical symptoms complicated with 
epilepsy
3 Carbamazepine (Tegretol) mood stabilizer or clinical symptoms complicated with 
epilepsy
4 Gabapentin (Neurontin) mood stabilizer or clinical symptoms complicated with 
neuropathic pain
5 Zolpidem (Ambien) most widely used hypnotic agent but alert in sleeping 
walk reported often
6 Zaleplon (Sonata) short acting for helping waking up in the middle of 
night
9
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4.2.4 Neuroleptics agents
Agitation, aggressive behavior, psychosis, and especially visual hallucinations are 
often encountered in the early stages, particularly in PDD compared to other types of 
dementia like AD or VD. For this reason, this class of medicines may be more often 
required in the early stage PDD compared to other types of dementia, but needs 
to be dosed and monitored closely. The second-generation antipsychotic agents or 
atypical antipsychotic agents are currently preferred due to their relatively tolerable 
side effect profiles with less risk of ‘neuroleptic sensitivity’, (i.e., motor, and cogni-
tive deterioration) [52]. Also, metabolic abnormalities, especially serum glucose 
increases, need to be closely monitored during treatment. Over sedation caused by 
high dose or frequent dosing should be discussed with family members or caregivers 
for adjusting neuroleptic doses promptly and safely. Institutional abuse of this class 
of medicine has been reported. These are common second-generation neuroleptics 
agents: (1) Quetiapine (Seroquel) 12.5 to 100 mg per day orally; (2) Olanzapine 
(Zyprexa) 2.5 to 10 mg per day orally; (3) Risperidone (Risperdal) 0.25 to 1 mg per 
day orally; (4) Aripiprazole (Abilify) 10 to 30 mg per day orally; (5) Ziprasidone 
(Geodon) 20 to 160 mg per orally.
4.2.5 Antidepressant medications
Geriatric depression is a common and treatable comorbidity in patients with 
dementia. Several tools are validated to screen for depression in older patients. The 
five-item Geriatric Depression Scale is brief and sensitive. It is as effective as the 
15-item Geriatric Depression Scale and does not require clinician administration 
[52]. In patients with depression and dementia, treatment for depression should 
usually be initiated first. Pseudodementia, or depression causing cognitive impair-
ment, is diagnosed if the impairment resolves with treatment of the depression. 
These antidepressant medications have been widely used for mild to moderate 
uncomplicated depression disorders in the primary care setting [53, 54]. Selective 
serotonin reuptake inhibitors (SSRIs) are the first line treatment of choice. Patients 
who do not respond to two or more SSRI agents may choose agents from the other 
group of antidepressants. These are commonly prescribed SSRI antidepressant 
medications: (1) Escitalopram 5 to 10 mg per day orally; (2) Citalopram 10 to 
20 mg per day orally; (3) Sertraline 25 to 100 mg per day orally; (4) Fluoxetine 
10 to 40 mg per day orally. Other antidepressants include: (1) Mirtazapine 7.5 to 
30 mg before bedtime orally; (2) Trazodone 50 to 150 mg before bedtime orally; 
(3) Bupropion 75 to 300 mg per day orally; (4) Venlafaxine 25 to 300 mg per day 
orally; (5) Nortriptyline 10 to 100 mg before bedtime orally. Three new antidepres-
sants are currently available. One is Vilazodone (Viibryd) that can be started at an 
initial dose of 10 mg orally once a day for 7 days, followed by 20 mg orally once a 
day for an additional 7 days, then a maintenance dose of 40 mg orally once a day. 
Medications commonly used in PCP setting for the pharmacologic management of PDD
7 Eszopiclone (Lunesta) effective hypnotic but dizziness and fainting caution in 
geriatric population
8 Ramelteon (Rozerem) quite safe agent but efficacy limited to certain 
population
9 Suvorexant (Belsomra) relatively new in market and quite safe agent but 
efficacy limited in higher dose
Table 4. 
Common medications for PDD patients.
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Second one is Levomilnacipran (Fetzima) with initial dose of 20 mg orally once a 
day for 2 days, then increased to 40 mg orally once a day; Maintenance dose: 40 to 
120 mg orally once a day. The third novel antidepressant is Vortioxetine (Trintellix) 
with dosage of 5 to 10 mg per day orally.
4.2.6 Anxiolytics, anticonvulsants, and hypnotic medications
In advanced disease stages, a significant portion of these patients develop 
behavioral disorders which are sometimes severe enough to incur a big burden, 
although not sensed well by patients themselves but mainly by caregivers and 
family members. Symptoms include anger with exploding tantrums, wandering, 
suspiciousness or paranoia, wakefulness at nighttime and incontinence, and inap-
propriate sexual behavior [55, 56].
Benzodiazepines can be carefully prescribed to the patients with agitation and 
anxiety, using a short acting agent, and on an as needed basis. While prescribing 
this class of medication, caution must be considered in high priority to balance 
potential side effects and clinical benefit. Best practices include starting with low 
dose treatment, while continually monitoring for fall incidence, declines in renal 
and hepatic function, lethargy, and any other undesirable side effects, especially in 
elderly patients.
5. Maintaining PDD patients’ general health
The most important aspect of the management of PDD is to maintain PDD 
patients’ general health in terms of preventive medicine, and to keep them as 
independent as possible in activities of daily living (ADL).
Since PDD, like PD itself, is not curable nor reversible, long-term or chronic 
ongoing care is the highlight of primary care practice. More than 30% of Parkinson’s 
disease patients will eventually develop dementia symptoms [57]. Therefore, early 
counseling and a scientific based clinical prediction to detect the subtle clinic 
symptoms of incipient dementia in this group of patients is an advantage that 
PCPs have over subspecialty physicians during their daily care and more frequent 
routine encounters. In the last decade, the guidelines for the Annual Wellness Visit 
(AWV) from Center for Medicare and Medicaid Service (CMS) has provided a good 
essential structure for PCPs to screen, predict, detect, and manage dementia among 
PD patients in daily proactive care [58, 59]. During an AWV visit, the companion of 
family members or caregivers is highly informative and sensitive to obtain informa-
tion about patients’ daily routine life patterns and memory status, and to detect 
subtle changes in their logical thinking and judgment. Current well-equipped 
telemedicine setups can provide an even better way of looking into patients’ living 
environment and other real-life situations around them. Periodic proactive moni-
toring, educational discussions, and prognosis counseling are the cornerstones 
for taking care of those patients and their family or caregivers. Disease burden, 
no doubt, is detrimental to the patient. However, family and caregivers’ stress 
and frustration cannot be ignored or underestimated during long-term, chronic 
stage, ongoing patient management. Especially, advanced PDD patients show 
hallucinations, wandering, suspiciousness and incontinence, and other behavioral 
symptoms. The management of these symptoms require tremendous efforts and 
resources from the caregiver [4, 8]. Early counseling and anticipating this potential 
development will prepare them psychologically in advance and help alleviate their 
stresses later. Also, making early arrangements to prepare for catastrophic happen-
ings can lead to better solutions using wider resources and options, and can help 
11
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avoid caregiver burnout. All these tasks are within the scope of the PCP’s practice. 
The following are the major tasks that PCPs should take care of for PDD patients 
from the beginning of disease to the end of their lives.
5.1 Annual wellness health maintenance
The mission for PCPs is to promote human beings’ wellbeing in aspects of 
general health and quality of life [60]. According to CMS requirement, recom-
mendations from the United States Preventive Task Force and every professional 
specialty association practice guideline, all patients including those with PDD 
must be routinely and properly screened yearly according to their age group. This 
includes mammograph for breast cancer; fecal occult blood test, Cologuard or colo-
noscopy accordingly for colon cancer, low dose chest CT for patients at high risk of 
lung cancer, PSA for high risk of prostate cancer, CBC for leukemia, AFP and liver 
sonography for liver cancer and so on, even though some clinical benefits are debat-
able. In most situations, all these cancer screenings are recommended to be held off 
at age 75 and above [58–60]. However, like anything in life, exceptions should be 
kept in mind for any individual whose lifespan could be more than 10 years from 
the day when the PCP performs these screening visits.
5.2 Schedule updating immunization
This group of PDD patients is predominantly within the category of senior 
citizens. They should follow the recommendation for immunizations per CMS 
guidelines (summarized in Table 5), based on the CDC’s Recommended Adult 
Immunization Schedule for ages 19 years or older, United States, 2021 [61].
5.3 Continuous care of concurrent medical conditions
Maintenance care for chronic illnesses, like hypertension, dyslipidemia, COPD, 
diabetes mellitus, depression, and chronic pain syndrome, should be routinely 
monitored. Relevant examination and adjustment of medications should be done 
as needed on an individual basis. The following should be considered accordingly: 
RetinaVue and urine microalbumin assay for diabetic retinopathy and nephropathy 
screening, spirometry for COPD evaluation, office-based tonometry for glaucoma 
screening, bone density measurement for females aged 65 and above and for males 
70 years and above, or for those who have a history of a fracture before the ages 
specified in the guidelines above [60].
5.4 Counseling patients and their families about PDD
The biggest efforts should be made to communicate thoroughly with patients 
and their families regarding disease pathophysiology, prognosis, updated treat-
ment guidelines and current options, potential consequences, or complications, 
and to patiently answer all questions sincerely and honestly in a professional 
manner [8, 19, 60]. A lengthy and respectful discussion with patients and their 
family members should be provided. For better results and efficiency, instruction 
should be given to patients or their families before the appointment, so that they 
can prepare their questions and do further research if they so choose. During the 
conference, attention should be paid politely. Use appropriate verbal and body 
languages and a comfortable office setting. Physicians should try to answer every 
single question, however, if time is limited or some difficulty arises, it is better to 
set up another appointment or location for further conversations, and to collect 
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different perspectives. In this situation, listening is far more important than lectur-
ing. Through this, PCPs might be able to understand a patients’ or families’ deep 
concern and real need, to recognize their under-the-table concerns, their inner 
voice, and agenda. At the end of the meeting, PCPs should make a summary and 
give a clear detailed picture of the treatment plan. Avoid using academic medical 
terminology whenever possible. Try to make sure that all medical information is 
delivered precisely and correctly, using lay language. Patients and their families 
should be well informed, allowing them to be part of the care team, and given many 
opportunities to be involved in the treatment, management, and planning. They 
should be convinced that everyone, including the patient, family, primary care 
provider, office supporting staff, and specialists are working together towards one 
goal of providing the best possible care to this individual patient and family.
5.5 General supportive measures
General support is important, not just for PDD patients, but also for their 
families. Nutritional status should be evaluated, addressed, and emphasized [62]. 
Nutrition cannot be overemphasized and should be discussed with the caregiver 
and family. A well-balanced high protein diet, with adequate daily calories, and 
liquid intake is essential. A handbook with detailed instructions for care planning 
should be provided for the caregivers. The Mediterranean diet, both alone and in 
combination with the Dietary Approach to Systolic Hypertension (DASH) diet, may 
be beneficial for the prevention of cognitive decline. Further research is needed to 
rule out potential confounds and to better characterize the mechanisms underly-
ing the role of nutrition in cognitive outcomes. Cessation of alcohol and cigarette 
smoking should be instructed. Supplement of vitamins, especially vitamin D and 
minerals (calcium, magnesium, zinc) should be discussed and encouraged.
Hearing loss and dementia often occur together, and hearing loss may be an 
independent but modifiable risk factor for subsequent dementia [63, 64]. PCPs 
should screen for hearing impairment and manage hearing aids for those who 
require them to help prevent faster deterioration of cognitive function. Patients 
should be encouraged to actively take part in socializing activities to maintain cog-
nitive stimulation, such as cooperating with caregivers, family members, support 
Vaccine Starting time Interval
Influenza vaccine Starting in autumn, until next 
spring at any age
1 dose annually
Pneumovax Starting at age 65 or younger with 
other comorbidities.
Prevnar 13 and Pneumovax 23; one 
dose each within one year apart.




Starting at age of 50 2-dose series RZV (Shingrix) 
2–6 months apart
Tetanus, diphtheria, and 
pertussis vaccination 
(Tdap, Td)
Tdap followed by 1 dose Td or 
Tdap at least 4 weeks after Tdap 
and another dose Td
Td or Tdap every 10 years
COVID-19 vaccine Starting at any age Pfizer and Moderna mRNA are given 
two doses with a 3- or 4-week interval. 
Johnson & Johnson’s is given one dose.*
*Boost dose may be needed according to the update information.
Table 5. 
Schedule updating immunization [61].
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networks, community resources and adult day care facilities. Patients should be 
arranged to participate in cognitively stimulating activities, e.g., reading, games, 
etc., and personally meaningful social activities, such as playing music, conversa-
tional interactions with others, family events, etc.
Over the past decade, insomnia has variably been associated with deficits in 
objective cognitive functioning, increased risk of dementia, and reductions in 
gray matter volume and white matter integrity in networks essential for cognitive 
functioning [65]. Sleep pattern and sleep hygiene guidance should be discussed in 
detail. Proper personal hygiene improves quality of life for patients, and also avoids 
irritation of the oral mucosa, the perineum area, and underneath the breasts, which 
can also improve the quality of sleep.
Prescribing hypnotic medications may be considered as needed. 
Benzodiazepines (BZDs) could be an option but should be used with caution. One 
study showed continuous exposure to BZDs and non-benzodiazepines (non-
BZDs) may contribute to the development of cognitive impairment. One should be 
careful when prescribing BZD or non-BZD hypnotics to patients with long-term 
insomnia, especially for those that are aged between 50 and 65 years. Additionally, 
it is best to use short acting sedatives at the lowest dosage for the therapeutic 
benefit, because greater exposure to these medications leads to a higher risk of 
developing dementia [65, 66].
The above approaches require cooperation with patients, families, caretakers, 
or the assisting living facilities. Although there is no concrete data to prove that 
the above approaches will delay the deterioration of cognitive function, these 
approaches will assuredly improve the quality of life for PDD patients.
5.6 Polypharmacy
Polypharmacy is another significant and epidemic issue. PCPs are at a critical 
and unique central position for this matter. In this age group, patients with PD are 
most likely struggling with multiple medical conditions, such as hypertension, high 
cholesterol, osteoarthritis, diabetes, malnutrition, depression, etc. Patients often 
visit different subspecialists such as cardiologists, nephrologists, neurologists, 
psychiatrists, ophthalmologists, endocrinologists, and dentists. It is a challenge to 
be vigilant with patients who have impaired cognitive function and are under the 
care of multiple physicians. It is particularly important to manage their medications 
to avoid drug interactions, unnecessary pills, conflict among prescriptions from 
different subspecialties, drug overdose, compliance issues, financial difficulty, 
monitoring medication refills and reconciliation of medications. Some studies 
reveal that polypharmacy was associated with cognitive decline in patients with 
newly diagnosed PD. Those findings suggest that medication reduction might serve 
as a promising intervention to prevent the development of dementia in patients 
with early PD [67, 68]. For fixed income senior citizens, financial challenge for 
medications is an important, but pragmatic issue to discuss. A PCP can help disad-
vantaged patients get into assistance programs from public or private sources and 
the pharmaceutical industry.
5.7 Neurology consultation
Neurologists are dependable and reliable allies and consultants in the care of 
PDD patients, but high-level care should be individualized. Once physician and 
patient relationships are established long-term, PCPs should be at the center of care 
planning. PCPs have the advantage of knowing and understanding patients better 
in terms of their medical and personal history, personality, habits, family members, 
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language, and cultural background. From that point of view, a PCP should be able 
to coordinate the best fitting specialists to take care of this individual within the 
guidelines of national and international standards [2, 8, 69].
6. Management of PDD patients in advanced stage
PD and dementia are incurable neurological conditions. PD patients who 
develop dementia usually progress to the advanced stages of disease. PDD patients 
often experience specific, complex, and varying needs along their disease trajec-
tory. A palliative approach to PDD should be discussed with patients, their caretak-
ers, and families in advance regarding management of the advanced stages of PDD, 
especially at the terminal periods. PDD patients may have several needs in the four 
domains of palliative care (physical, psychological, social, and spiritual) in addi-
tion to specific needs for a peaceful, familiar environment, and practical support 
[70–72]. “Person-centered care, communication and shared decision making” is 
among the most important domains of palliative care in dementia [73]. An algo-
rithm for the evaluation and management of PDD patients across the disease stages 
is depicted in Figure 2, summarizing much of the above recommendations.
6.1 Counseling and guidance for advance medical directive
Counseling for advance medical directive (AMD) or advance care planning 
(ACP) should be routine care tasks for PCPs. Medical and advance care directives 
(e.g., designation of power of attorney) should be discussed as early as possible 
while the mental functions of patients are still competent, allowing patients and 
their families to have enough time to discuss and plan. ACP is a special form of 
ongoing communication about preferred future health care [70]. Long-term health 
care planning (e.g., living arrangements in the late stage of dementia) and financial 
planning are other important issues for patients and families to discuss and plan 
well in advance. In California, the Physician Orders for Life-Sustaining Treatment 
form or POLST (pink form) is routinely used in the PCP’s office for the purpose 
of making the patients’ advanced directives clear and easily obtainable. Physicians 
should explain the meaning and the consequences of the decision making with 
patients and family in detail. This process should be highly informative and provide 
guidance so that patients may come to their informed decision comfortably.
6.2 Management of advanced disease
To optimally promote quality of life and death of a person affected by a com-
plex, incurable, and life-threatening health problem, such as dementia, care teams 
must address the person’s physical, emotional, psychosocial and spiritual needs, 
as summarized in the WHO definition of palliative care. Dementia usually occurs 
during the later stages in PD, when clinical symptoms could be progressing quite 
rapidly, complicated by aging and other comorbidities. Once PD reaches such an 
advanced stage, the approach towards care should shift towards palliative care, 
or its consideration. Palliative care can start in the form of ACP if the patient and 
family caregiver are willing to talk about the future soon after the diagnosis of PDD. 
The focus of care should be well planned, but simple with straightforward symptom 
management. Care of the person, not disease per se, is important. This approach 
includes attention to physical, mental, social, and spiritual aspects, especially since 
there are no cures available with current interventions. Figure 3 outlines a model 
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for palliative care of PDD patients. The palliative care should be carried out by a 
comprehensive team which includes physicians as leaders, registered nurses, office 
supportive staff, social workers, religious leaders, family members and/or support-
ing network, a disease focus group and so forth. An in-home model of palliative 
care for homebound advanced PD and PDD patients was recently introduced in 
2020, which highlights the importance of medication reconciliation, home safety 
assessments, and appropriate monitoring and treatment of orthostatic hypotension, 
a leading cause of falls [71]. At this stage not only patients’ needs, but also families’ 
needs should be addressed. Options like assisted living homes, boarding care, and 
skilled nurse facilities should be discussed when those needs arise. The goal at an 
advanced stage, which may eventually progress to the level of hospice care, is to 
minimize the suffering and improve the quality of life for both patients and their 
families or caregivers.
6.3 Pain control
Pain is often difficult to assess in people with advanced dementia due to loss 
of communicative ability [74]. This can result in patient concerns about pain not 
being heard or being misinterpreted. Communication difficulties are a chal-
lenge to practitioners because there may be several possible causes of distress 
and possibly no particular localizing behaviors or signs associated with pain in 
an individual with dementia [72]. Agitation is a frequent symptom in dementia 
patients and may be associated with untreated pain. Studies show that agitation 
and aggressive symptoms decrease when pain is effectively treated [75]. Proper 
and effective pain control and the judicious utilization of opioid and benzodiaz-
epine medications during palliative care is a critical step in successful care. Pain 
is distressful for both patients and their families and can trigger a cascade of 
other symptoms. For best results, a specialized pain management team, trained 
nurse practitioner or physician assistant may be consulted or invited into the 
care team. Fortunately, in the current healthcare system of the United States of 
America, well designed palliative care/hospice enterprises are established, and 
widely available for primary care physicians to adopt and refer their patients and 
families. This facilitates a well-designed, professional, and individually tailored 
optimal palliative care plan for the many stresses and discomforts associated with 
end of life.
Figure 3. 
Model for palliative care of PDD patients.
Dementia in Parkinson’s Disease
16
6.4 Social needs management
The burden of caring for a dementia patient may be physical/medical (e.g., 
neglect of caregiver’s own health, with potential medical complications), emotional 
and psychological (stress, burnout, depression), and/or financial. Prevention, 
early recognition, and treatment of these issues (e.g., referrals to social work for 
additional support), are integral to an effective management plan [76]. PCPs should 
engage the office staff, benefit and personnel specialists, and social workers in 
dealing with disease stage transitioning, personal financial issues, and interfamilial 
relationships. They, in many cases, need to activate available funding sources at the 
state and federal levels. Questions regarding the patient’s driving safety and privi-
leges should be raised at the appropriate time and stage of the disease. PCPs are the 
advocates of patients in protecting their loved ones from becoming burned out due 
to the long term duties of caregiving. In the end, PCPs function as liaisons on behalf 
of patients and their caregivers in not only coping with but also fighting against this 
devastating disease.
7. Conclusions
PCPs play an important role in the management of PDD patients. The art of 
practice for PCPs includes knowing when and how to introduce a comprehensive 
ongoing care plan for individual PDD patients. A comprehensive ongoing care 
plan includes (1) screening for changes in mental function regularly, (2) properly 
diagnosing PDD, (3) applying nonpharmacologic and pharmacologic interventions 
accordingly, (4) orchestrating multidisciplinary care, special therapies, and aux-
iliary support accordingly, (5) consulting advance medical directive and palliative 
care early. The optimal goal is to maintain relative independence for PDD patients, 
if this is safe. It is reasonable and proper to initiate palliative care and hospice for 
PDD patients in the advanced stage to provide better qualities of their later life 
experience.
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